TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07795164: Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

Sponsor: Altimmune, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1800 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07795164 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07795164 Rescue Dossier →